Predict your next investment

HEALTHCARE | Biotechnology
patarapharma.com

See what CB Insights has to offer

Stage

Unattributed | Dead

Total Raised

$40.8M

Last Raised

$6M

About Patara Pharma

Patara Pharma is a privately-held, San Diego-based, clinical-stage biotechnology company developing new therapeutics that target debilitating allergic and inflammatory diseases and conditions in orphan or focused patient populations. The company's lead candidate, PA101B, is a proprietary formulation of a GPR35 agonist with anti-allergy and anti-inflammatory properties. PA101B is being evaluated in separate Phase II clinical trials for the treatment of refractory chronic cough and the treatment of indolent systemic mastocytosis.

Patara Pharma Headquarter Location

11455 El Camino Real Suite 460

San Diego, California, 92130,

United States

619-540-3118

Latest Patara Pharma News

Roivant launches lung-focused Respivant with phase 2 IPF drug

Sep 18, 2018

Sep 18, 2018 9:05am Respivant plans to launch a phase 2b trial of its idiopathic pulmonary fibrosis cough drug in early 2019. (Pixabay) Roivant Sciences’ spinout machine keeps turning, with the launch of the lung-disease focused Respivant Sciences, a company built around an inhaled drug for treating chronic cough in patients with idiopathic pulmonary fibrosis. Vivek Ramaswamy’s latest “vant ," based in San Diego, will be led by CEO Bill Gerhart, alongside its executive vice president for clinical and regulatory affairs, Ahmet Tutuncu, M.D., Ph.D., and executive VP for development and manufacturing, Pravin Soni, Ph.D. Respivant's RVT-1601 was acquired earlier this month from Patara Pharma—as were Gerhart, Tutuncu and Soni themselves, who had served as Patara’s co-founders and executive team. In 2015 , the company raised $26 million in venture capital to develop the cough medicine. Subscribe to FierceBiotech! Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox! Formerly known as PA101, the drug is an inhaled cromolyn sodium anti-inflammatory delivered with a proprietary nebulizer. It acts as a mast-cell stabilizer with immune-modulating properties that block the release of histamines. "Almost all IPF patients suffer from a dry, persistent chronic cough, and for many of them this cough can have a debilitating physical and psychosocial impact on their quality of life," said Gerhart, formerly CEO of Patara, which conducted the drug’s initial development. Respivant estimates that about 115,000 adults in the U.S. have IPF, as well as 3 million to 5 million worldwide. In a phase 2a clinical trial, the drug showed statistically significant reductions in cough frequency among IPF patients after two weeks of treatment. Respivant plans to begin its own clinical work, with a phase 2b study, in the first quarter of next year. Before Patara, Gerhart was president and CEO of Elevation Pharmaceuticals, which was acquired in 2012 by Sunovion. Elevation’s inhaled COPD therapy would later be marketed as Lonhala Magnair. Tutuncu and Soni, meanwhile, had served as chief medical officer and chief technology officer, respectively, at both Patara and Elevation as well. The move closes the book on Patara Pharma: A statement on the company's website described PA101 as its only asset, and said it would cease operations following its deal with Roivant.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Patara Pharma Patents

Patara Pharma has filed 14 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Dosage forms
  • Drug delivery devices
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/5/2016

4/23/2019

Cytokines, Clusters of differentiation, Monoclonal antibodies, Interleukins, Dosage forms

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/5/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

4/23/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Cytokines, Clusters of differentiation, Monoclonal antibodies, Interleukins, Dosage forms

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.